Target intelligence / Profile preview

Lactobacillus helveticus

Molecular classification
Other (Probiotic bacterium; not a protein, receptor, or enzyme)
01

Overview

Lactobacillus helveticus is a Gram-positive, acid-tolerant, non-spore-forming lactic acid bacterium widely used in dairy fermentation and evaluated as a probiotic. It can colonize the gastrointestinal tract, where it exerts health-promoting functions such as modulating the gut microbiota, increasing production of beneficial short-chain fatty acids, antagonizing enteric pathogens, and attenuating inflammation. Colonization depends on traits like adhesion factors (e.g., S-layer and mucus-binding proteins), exopolysaccharide production, and metabolic adaptability. Its benefits are strain-specific, with select strains notably mitigating diarrheal diseases and favorably altering gut immune responses and barrier integrity

Other names
L. helveticusLactobacillus helveticus (alternative spelling/presentation)
02

Mechanism of action

Competitive exclusion of pathogens (by colonizing and occupying niches); Enhancement of short-chain fatty acid (SCFA) production (e.g., butyrate, propionate, acetate); Modulation of immune signaling and cytokine production (downregulation of pro-inflammatory cytokines TNF-α, IFN-γ, IL-6; upregulation of IL-10); Restoration of water balance (upregulation of aquaporin 3); Degradation/detoxification of toxins; Strengthening of epithelial barrier function

03

Biological functions

Gut microbiota modulationShort-chain fatty acid productionAntagonism of pathogensImmune modulationMaintenance of barrier functionDetoxification of xenobiotics and harmful compounds
04

Disease associations

Infection (mitigation of enteric infections, e.g., Escherichia coli–induced diarrhea)Inflammation (attenuation of intestinal inflammation)Cancer (protection against colorectal cancer through butyrate production)Other (general maintenance of gastrointestinal health)
05

Safety considerations

Generally recognized as safe (GRAS)Low risk of antibiotic resistance transfer (screened in quality probiotic strains)Rare, theoretical risk of infection in severely immunocompromised hosts
06

Biomarkers

Fecal SCFA levels (butyrate, acetate, propionate)Expression of gut barrier proteins (e.g., AQP3)Inflammatory cytokines (TNF-α, IL-6, IFN-γ, IL-10)Microbial composition (increased abundance of beneficial genera, restoration of diversity)

Beyond the preview

Go deeper on Lactobacillus helveticus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus helveticus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call